Vetter, a contract development and manufacturing organization (CDMO), has successfully commercialized eight customer drug products as of the end of 2023, supported by the comprehensive portfolio of the Vetter Development Service during their drug development phases.
 
The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases, among others. Their nature and administration vary widely, ranging from emergency medications to long-term and life-enhancing therapies for patients. The drugs also vary in delivery methods, which include self-administration for at-home care and administration by healthcare professionals.
 
“Bringing a promising therapy through the clinical phase to market readiness and launch is a challenging journey that culminates years of development work. Our holistic development service offerings build on one another and become interlinked,” shared Dr. Claus Feussner, Senior Vice President Vetter Development Service. “This allows us to support our customer’s products throughout the entire development cycle to commercialization and beyond. Our individualized capabilities have allowed us to support more than 50 market launches over the past five years.”
 
Vetter has significantly expanded its clinical capabilities in recent years, both in terms of production capacity, analytical offerings, and personnel. The Vetter Development Service is one of the three pillars of the CDMO, complementing Vetter Commercial Manufacturing and Vetter Secondary Packaging and Assembly.
 
The CDMO is currently supporting more than 200 projects in early and late clinical phases as well as life-cycle development.